Evidence map›Paper›PMID 33544936›Full record

ArticleMolecular carcinogenesis2021

Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP.

Jyotsana Singhal, Prakash Kulkarni, David Horne, Sanjay Awasthi, Ravi Salgia, Sharad S Singhal

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular carcinogenesis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jyotsana SinghalDepartments of Medical Oncology, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, California, USA.
Prakash KulkarniDepartments of Medical Oncology, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, California, USA.
David HorneDepartments of Molecular Medicine, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, California, USA.
Sanjay AwasthiDepartment of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Ravi SalgiaDepartments of Medical Oncology, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, California, USA.
Sharad S SinghalDepartments of Medical Oncology, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, California, USA.
City Of Hope National Medical Center · USTexas Tech University · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

The overexpression and amplification of the protooncogene neu (ERBB2) play an important role in the development of aggressive breast cancer (BC) in humans. Ral-interacting protein (RLIP), a modular stress-response protein with pleiotropic functions, is overexpressed in several types of cancer, including BC. Here, we show that blocking RLIP attenuates the deleterious effects caused by the loss of the tumor suppressor p53 and inhibits the growth of human BC both in vitro and in vivo in MMTV-neu mice. In addition, we show that treatment with the diet-derived, RLIP-targeting chemotherapeutic 2'-hydroxyflavanone (2HF), alone or in combination with RLIP-specific antisense RNA or antibodies, significantly reduced the cumulative incidence and/or burden of mammary hyperplasia and carcinoma in MMTV-neu mice. 2HF treatment correlated with reduced tumor cell proliferation and increased apoptosis, and the average number of Ki67-positive (proliferating) cells was significantly lower in the tumors of 2HF-treated mice than in the tumors of control mice. Furthermore, targeting RLIP also resulted in the overexpression of E-cadherin and the infiltration of CD3

Indexed as

AnimalsAnticarcinogenic AgentsATP-Binding Cassette TransportersBreast NeoplasmsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleFlavanonesGTPase-Activating ProteinsHumansLymphocytes, Tumor-InfiltratingMammary Glands, AnimalMammary Neoplasms, ExperimentalMice, TransgenicMolecular Targeted TherapyProto-Oncogene Proteins c-akt2'-hydroxyflavanoneAnticarcinogenic AgentsATP-Binding Cassette TransportersErbb2 protein, mouseErb-b2 Receptor Tyrosine KinasesFlavanonesGTPase-Activating ProteinsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2RALBP1 protein, humanRalbp1 protein, mousebreast cancerMMTV-neu micepreventionRalBP1RLIP

Identifiers

PMID33544936
PMCPMC7952002
OpenAlexW3128911469

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.